Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, gives an overview of a study (NCT02133742) looking at pembrolizumab combined with axitinib for the first-line treatment of advanced kidney cancer. Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Plimack hopes this combination can become the new frontline standard of care in renal oncology.
Exciting potential of pembrolizumab combined with axitinib for kidney cancer
